U.S. market Closed. Opens in 11 hours 45 minutes

FULC | Fulcrum Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue2.81M6.34M19.16M8.82MN/AN/AN/A
Cost of Revenue2.17M2.41M2.52M2.38M2.05MN/AN/A
Gross Profit633.00K3.93M16.65M6.44M-2.05MN/AN/A
Operating Expenses111.30M118.48M100.22M80.43M84.22M33.50M22.99M
Selling, General & Admin39.50M41.69M30.52M21.39M13.14M8.31M4.50M
Research & Development71.80M76.78M69.70M59.04M71.07M25.18M18.49M
Other Operating Expenses13.33M2.69M207.00K792.00K29.00K392.00KN/A
Operating Income-110.66M-112.56M-81.05M-71.61M-84.22M-33.50M-22.99M
Other Expenses / Income13.33M2.69M207.00K792.00K1.54M392.00K29.00K
Before Tax Income-97.33M-109.87M-80.85M-70.82M-82.68M-32.59M-22.96M
Income Tax Expenses2.00M-4.25M-2.52M-2.38M-3.56M910.00KN/A
Net Income-97.33M-105.62M-78.33M-68.44M-79.11M-32.59M-22.96M
Interest ExpensesN/A-2.69MN/AN/AN/AN/AN/A
Basic Shares Outstanding61.31M44.99M35.36M25.35M11.05M16.94M10.95M
Diluted Shares Outstanding61.31M44.99M35.36M25.35M11.05M16.94M10.95M
EBITDA-108.49M-111.71M-81.05M-71.61M-84.22M-32.15M-22.25M
EBITDA Margin-3,867.81%-1,761.38%-422.97%-811.64%0.00%0.00%0.00%
EBIT-95.33M-112.56M-80.85M-70.82M-82.68M-31.68M-22.96M
EBIT Margin-3,398.61%-1,774.85%-421.89%-802.66%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙